An Updated Systematic Review of Cost‑Effectiveness Analyses of Drugs for Osteoporosis by Li, N. et al.
Vol.:(0123456789)
PharmacoEconomics (2021) 39:181–209 
https://doi.org/10.1007/s40273-020-00965-9
SYSTEMATIC REVIEW
An Updated Systematic Review of Cost‑Effectiveness Analyses of Drugs 
for Osteoporosis
Nannan Li1 · Dennis Cornelissen1 · Stuart Silverman2 · Daniel Pinto3 · Lei Si4,5 · Ingrid Kremer1 · Sandrine Bours6 · 
Robin de Bot1,7 · Annelies Boonen6 · Silvia Evers1 · Joop van den Bergh8,9,10 · Jean‑Yves Reginster11 · 
Mickaël Hiligsmann1 
Accepted: 19 September 2020 / Published online: 7 October 2020 
© The Author(s) 2020
Abstract
Background Considering the heavy economic burden of osteoporotic fractures, the limits of healthcare resources, and the 
recent availability of new anti-osteoporosis drugs, there is continuing interest in economic evaluation studies of osteoporosis 
management strategies.
Objectives This study aims to (1) systematically review recent economic evaluations of drugs for osteoporosis and (2) to 
apply an osteoporosis-specific guideline to critically appraise them.
Methods A literature search was undertaken using PubMed, EMBASE, National Health Service Economic Evaluation 
database, and the Cost-Effectiveness Analysis Registry to identify original articles containing economic evaluations of 
anti-osteoporosis drugs, published between 1 July, 2013 and 31 December, 2019. A recent European Society for Clinical 
and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases-International Osteoporosis Founda-
tion (ESCEO-IOF) guideline for the conduct and reporting of economic evaluations in osteoporosis was used to assess the 
quality of included articles.
Results The database search retrieved 3860 records, of which 27 studies fulfilled the inclusion criteria. These studies were 
conducted in 15 countries; 12 active drugs were assessed, including various traditional pharmacological treatments such as 
bisphosphonates, raloxifene, strontium ranelate, denosumab, and teriparatide, and new agents such as abaloparatide, romo-
sozumab, and gastro-resistant risedronate. Eight out of 12 studies that compared traditional oral bisphosphonates to other 
active interventions (denosumab, zoledronic acid, gastro-resistant risedronate, and teriparatide) suggested that the other 
active agents were generally cost-effective or dominant. Additionally, the cost-effectiveness of sequential therapy has recently 
been assessed and indications are that it can lead to extra health benefits (larger gains in quality-adjusted life-year). The key 
drivers of cost effectiveness included baseline fracture risk, drug effect on the risk of fractures, drug cost, and medication 
adherence/persistence. The current average score for quality assessment was 17 out of 25 (range 2–15); room for improve-
ment was observed for most studies, which could potentially be explained by the fact that most studies were published prior 
to the osteoporosis-specific guideline. Greater adherence to guideline recommendations was expected for future studies. The 
quality of reporting was also suboptimal, especially with regard to treatment side effects, treatment effect after discontinu-
ation, and medication adherence.
Conclusions This updated review provides an overview of recently published cost-effectiveness analyses. In comparison with 
a previous review, recent economic evaluations of anti-osteoporosis drugs were conducted in more countries and included 
more active drugs and sequential therapy as interventions/comparators. The updated economic evidence could help decision 
makers prioritize health interventions and the unmet/unreported quality issues indicated by the osteoporosis-specific guideline 
could be useful in improving the transparency, quality, and comparability of future economic evaluations in osteoporosis.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4027 3-020-00965 -9) contains 
supplementary material, which is available to authorized users.
Extended author information available on the last page of the article
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Key Points for Decision Makers 
In comparison with oral bisphosphonates (including 
generic forms), other active interventions (such as deno-
sumab, zoledronic acid, gastro-resistant risedronate, or 
teriparatide) were generally cost effective or dominant
Sequential therapy has the potential to generate extra 
health benefits and to be cost effective in comparison 
with monotherapy, although more clinical and economic 
data are needed
Although several studies partially followed the European 
Society for Clinical and Economic Aspects of Osteo-
porosis, Osteoarthritis and Musculoskeletal Diseases-
International Osteoporosis Foundation guideline, quality 
was largely insufficient for most articles. Our study 
highlighted that insufficiently implemented and/or 
reported recommendations should be included in future 
studies; this could be useful in improving the transpar-
ency, quality, and comparability of economic evaluations 
in osteoporosis
1 Introduction
Osteoporosis is a skeletal disease associated with a sig-
nificant health and economic burden, which has become 
an increasing global health problem considering the aging 
population characterized by multi-morbidity. The morbidity 
and mortality imposed by osteoporotic fractures along with 
the negative impact on patients’ quality of life are important 
clinical considerations [1]. Worldwide, osteoporosis causes 
more than 8.9 million fractures annually, resulting in an 
osteoporotic fracture every 3 s [2]. In the European Union, 
22 million women and 5.5 million men had osteoporosis in 
2010 [3]. As a result of changes in population demography, 
the annual number of fragility fractures was expected to rise 
from 3.5 million in 2010 to 4.5 million in 2025, correspond-
ing to an increase of 28% [4]. In the USA, over 1.5 million 
fractures per year were attributable to osteoporosis, resulting 
in direct healthcare costs of 12–18 billion US dollars [5]. 
Improving osteoporosis care and reducing spiraling fracture-
related costs pose worldwide challenges.
Health economic evaluations have become increasingly 
important to support the setting of priorities in healthcare 
and to help decision makers allocate healthcare resources 
efficiently in the context of limited healthcare resources, 
the ongoing aging of the population, and the heavy 
economic burden of osteoporotic fractures, as well as the 
recent availability of new agents for osteoporosis manage-
ment (e.g., abaloparatide, romosozumab, gastro-resistant 
risedronate). In 2015, a study systematically reviewed 
all economic evaluations of anti-osteoporosis drugs pub-
lished up to 31 June, 2013 and suggested that anti-osteo-
porosis drugs were generally cost effective in comparison 
with no treatment in postmenopausal women aged over 
60–65 years with low bone mass, especially those with 
prior vertebral fractures. However, given the heterogene-
ity of fracture risk, comparators, country setting, model 
structure, and incorporation of medication adherence, as 
well as the lack of head-to-head comparisons, it remained 
challenging to make comparisons between studies [6]. In 
addition, the quality of reporting was largely insufficient 
for most studies, despite the fact that guidelines for con-
ducting health economic evaluations have been widely 
available for many years.
Recently, a guideline for the conduct and reporting of 
economic evaluations in the field of osteoporosis has been 
designed by a working group convened by the European 
Society for Clinical and Economic Aspects of Osteo-
porosis, Osteoarthritis and Musculoskeletal Diseases 
(ESCEO) and the US branch of the International Osteo-
porosis Foundation (IOF) [7]. Although several disease-
specific recommendations for economic evaluations have 
been developed, this guideline is the first that provides a 
list of recommendations and minimum requirements for 
the design, conduct, and reporting of an osteoporosis-
specific economic evaluation. Osteoporosis-specific 
recommendations in this guideline, which supplement 
general and national guidelines, could guide research-
ers in designing appropriate and high-quality economic 
evaluations and help decision makers and reviewers to 
assess the quality of these studies, and further to improve 
the transparency and comparability of these studies and 
maintain methodologic standards [7]. Therefore, assess-
ing how recent studies adhere to the osteoporosis-specific 
guideline is important in identifying the main limitations 
of these studies, and further to indicate some of the most 
important recommendations that should be taken into 
account in future studies.
An overview of currently available studies regard-
ing cost-effectiveness analyses of drugs for osteoporosis 
would thus be useful to guide researchers in designing 
and conducting high-quality economic evaluations, in 
identifying gaps in current evidence, and to help admin-
istrators make decisions based on high-quality evidence. 
We therefore updated and undertook this review to (1) 
systematically identify and review economic evaluations 
published between 2013 and 2019 on drugs for osteopo-
rosis and (2) to critically appraise their quality using the 
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recent osteoporosis-specific guideline, and also to provide 
insight into key drivers of cost-effectiveness ratios.
2  Methods
2.1  Literature Search
A systematic literature search was undertaken to identify 
recent cost-effectiveness analyses of drugs for osteopo-
rosis according to the Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses (PRISMA) guideline 
[8]. The search was conducted using several databases 
including PubMed, EMBASE (Ovid), National Health 
Service Economic Evaluation Database (NHS EED) [the 
database ceased to be updated after March 2015] and the 
Cost-Effectiveness Analysis (CEA) Registry (the database 
can serve as an archive only until 2018). We restricted 
our analysis to articles published between 1 July, 2013 
and 31 December, 2019, as prior articles were covered in 
the previous review [6]. An initial search was conducted 
in PubMed and EMBASE using a search strategy (see 
Appendix 1 in the Electronic Supplementary Material 
[ESM]) designed according to the Population, Interven-
tion, Comparator, Outcome (PICO) criteria with the help 
of an expert library specialist. The key word ‘osteopo-
rosis’ was used in the NHS EED and the CEA Registry 
database.
2.2  Study Selection
First, duplicates were identified and removed. Second, 
two reviewers (NL, DC) independently applied inclusion 
and exclusion criteria to screen titles and abstracts of the 
remaining articles. Third, full-text versions of eligible arti-
cles were screened in-depth by two independent reviewers 
(NL and DC, LS, DP, SS, or RB). A consensus meeting 
with a third reviewer (MH) was used to resolve discrepan-
cies. Finally, reference lists and citations of eligible arti-
cles were checked manually for additional relevant studies.
Studies were included if they were published in Eng-
lish between July 2013 and December 2019 and contained 
a full economic evaluation (the comparative analysis of 
alternative interventions in terms of both costs and conse-
quences) of anti-osteoporosis drugs. Non-original articles 
(e.g., editorials, reviews, conference proceedings), partial 
economic evaluations, and non-specific drug studies (e.g., 
only use vitamin D and/or calcium as interventions, stud-
ies regarding screening strategies, intervention thresholds, 
medication adherence, nutrition, model of care, fracture 
liaison services, and lifestyle) were excluded.
2.3  Data Extraction and Quality Assessment
A standardized data-extraction form was developed to col-
lect data from eligible studies. Study characteristics regard-
ing publication (author, year of publication, journal), study 
design (country, population, perspective, model type, out-
come measure, time horizon, comparators, intervention 
duration, cost type, discount rates, year of valuation), study 
outcomes (results and sensitivity analysis), and funding 
source were extracted by one reviewer (NL) and checked by 
another reviewer (DC, LS, DP, SS, RB, or IK). Incremen-
tal cost-effectiveness ratios (ICERs) were reported as pro-
vided in the articles. Afterwards, for comparability reasons, 
all ICERs were converted into 2019 US dollars using the 
Organisation for Economic Cooperation and Development 
exchange rate and inflation rate [9]. We then synthetized and 
analyzed ICERs of active agents compared to traditional oral 
bisphosphonates (first-line treatments in most countries), 
and of sequential therapies (e.g., abaloparatide/teriparatide 
followed by alendronate) by using US$100,000 per quality-
adjusted life-year (QALY) gained as the willingness-to-pay 
(WTP) threshold. Other information such as country, treat-
ment duration, and annual drug cost was also extracted. In 
addition, we checked included studies, especially one-way 
sensitivity analyses, to identify key drivers of cost effective-
ness; these were eventually chosen through team discussion.
The conduct and reporting quality of included articles 
were then appraised using the ESCEO-IOF guideline for 
economic evaluations in osteoporosis by two independent 
reviewers (NL with DC, LS, DP, SS, RB, or IK). The whole 
assessment consisted of two parts. Part one included recom-
mendations for the design and conduct of an economic eval-
uation in osteoporosis; 29 recommendations were addressed 
in nine categories (type of economic evaluation, method for 
the conduct of economic evaluation, modeling technique, 
base-case analysis and population, mortality, fracture costs 
and utility, treatment characteristics, sensitivity analyses, 
and outcomes). Part two was an osteoporosis-specific check-
list with nine recommendations for reporting, including the 
reporting and justification of key modeling aspects (choice 
of model, transition probabilities, effect of fracture on costs, 
mortality, and utility) and key treatment characteristics (the 
effect of treatment per fracture site, the effect of treatment 
after discontinuation, the inclusion and approach used to 
model medication adherence, therapy costs, and side effects) 
[7].
Each recommendation of these two parts was scored 
using ‘Yes’ (fulfilled the requirement of reporting), ‘No’ 
(did not fulfill the requirement), ‘Part’ (partially fulfilled the 
requirement), or ‘Not Applicable’ according to the opera-
tionalization of the guideline (Appendix 2 in the ESM). To 
estimate a score for reporting, we assigned a score of 1 for 
‘Yes’, 0.5 for ‘Part’, and 0 for ‘No’. Discrepancies in rating 
184 N. Li et al.
were resolved by consensus and consultation with a third 
reviewer (MH). It is worth noting that in the scoring sys-
tem we excluded recommendations that were not directly 
connected to the quality level of studies (i.e., ‘use ICUROS 
data’, ‘use  FRAX® or  GARVAN® tools’, ‘consider sequential 
therapy as intervention’, and ‘in the absence of hip/wrist 
specific efficacy data, use non-vertebral or clinical fracture 
efficacy data as replacement’).
3  Results
3.1  Results of Study Selection
Figure 1 shows the PRISMA flowchart for the identification 
of studies. The database search retrieved 3860 records, of 
which 620 were found to be duplicates and removed. We 
reviewed all titles and abstracts of the remaining 3240 stud-
ies and subsequently excluded 3188 articles that did not meet 
our inclusion criteria. Upon review of the full text of the 
remaining 52 studies, 25 articles were excluded for reasons 
such as being non-original articles (n = 2), partial-economic 
evaluations (n = 4), reporting on non-specific drugs (n = 13), 
and studies included in previous review (n = 6). A total of 27 
articles were included in our study for data extraction and 
quality assessment.
3.2  Overview of Included Studies
The characteristics of included studies are reported in 
Table 1. These studies were conducted in 15 different coun-
tries. The USA accounted for the largest number (n = 7); 
12 studies were conducted in Asia, i.e., three each in Japan 























Records identified through database searching 
(n =3860) 
              PubMed:1893         Embase:1898 
              CEA registry:44     NHS EED:25
Records after duplicates removed 
(n =3240) 
Abstract and title screened 
(n = 3240) 
Records excluded 
(n =3188) 
Full-text articles assessed for 
eligibility 
(n =52) 






Articles included in previous 
systematic review:6 
Studies included in 
qualitative synthesis 
(n = 27) 
Fig. 1  Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart of study selection. CEA cost-effectiveness 
analysis, NHS EED National Health Service Economic Evaluation database
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performed in five different European countries. Twelve of 
the 27 studies were published in osteoporosis journals, par-
ticularly in Osteoporosis International (n = 5).
Most studies used the healthcare perspective (n = 21), 
some with a societal perspective (n = 4), while one study 
used both societal and healthcare perspectives, and another 
study reported societal, healthcare, and governmental per-
spectives. All studies included direct costs and only three 
also considered indirect costs [15, 18, 20]. However, we 
found that some studies including both direct and indirect 
costs were not defined as having a societal perspective, 
although this was the original information stated by authors 
reported in Table 1; no adjustment and correction were 
made for this. Nineteen studies applied a lifetime horizon 
while others considered truncated time horizons [10–15]. 
A Markov model was used in 21 studies, consisting of a 
Markov cohort model (n = 12) or a Markov microsimulation 
model (n = 9). One study applied a discrete-event simula-
tion model [16], another a decision-tree model [13]. Quality-
adjusted life-years (QALYs) were used as the outcome in 
these 23 studies with a model. The remaining four studies 
used no model [10–12, 17]. One out of the four conducted 
a cost-minimization analysis [10], in which costs were 
compared. Another two studies [11, 12] used bone mineral 
density (BMD) as the final outcome and ICER was calcu-
lated based on the differences of costs and BMD of different 
interventions. Furthermore, the number of fracture events 
was regarded as the outcome in the fourth study [17], ICER 
was calculated based on the differences of average annual 
costs divided by the difference of numbers of hip fractures 
prevented between bisphosphonates and the combination of 
calcium and vitamin D. Fourteen studies were funded by 
pharmaceutical companies or national public funds, while 
13 studies did not mention the source of funding or had no 
funding.
Table 2 presents characteristics of the studied popula-
tion, the active intervention and comparator, year of costing 
valuation, sensitivity analysis, and the main results of the 
articles. Study populations differed between studies in BMD 
T-score, mean age, history of fracture, or even tolerance of 
oral bisphosphonates. Some studies included patients strati-
fied for age and two studies included only a male population 
[21, 22].
Twelve active drugs were assessed in the studies, includ-
ing various pharmacological treatments such as bisphospho-
nates (alendronate, etidronate, risedronate, ibandronate, and 
zoledronic acid), raloxifene, strontium ranelate, denosumab, 
and teriparatide, and including new agents such as abalo-
paratide, romosozumab, and gastro-resistant risedronate. 
Twelve studies included two or more active drugs in their 
analysis [13, 15–17, 21–28]. Oral bisphosphonates were 
included in 11 studies [13–15, 18, 21, 22, 24–26, 29, 30] 
and compared with other active interventions. There were 
three studies [16, 20, 28] considering sequential therapies as 
comparators, while six studies [15, 17, 30–32, 36] made the 
comparison between active osteoporotic drugs and calcium/
vitamin  D3 and ten studies [12, 18, 19, 23–25, 27–29, 33, 34] 
included no treatment as the comparator. Treatment duration 
in most studies was similar to randomized controlled trials, 
indications, or guidelines (e.g., 3 or 5 years for anti-resoptive 
agents, 12–24 months for anabolic agents). Both a deter-
ministic sensitivity analysis (e.g., one-way, multivariate) 
and a probabilistic sensitivity analysis were conducted in 
17 studies. Two studies [24, 26] applied only a probabilistic 
sensitivity analysis and three studies applied only a one-way 
sensitivity analysis [13, 32, 34]. Sensitivity analysis was not 
conducted in five studies [10–12, 17, 35]. We presented the 
WTP threshold in Table 2 as stated by the authors and no 
adjustment was made. The WTP threshold was shown to be 
different even through studies had been conducted in the 
context of the same country.
Table 3 summarizes the results of the cost-effectiveness 
analysis between traditional oral bisphosphonates and other 
active drugs in 2019 US dollars. Annual drug costs for 
branded oral bisphosphonates had a range from US$123 
to US$1874; the cost for generic oral bisphosphonates was 
much lower, from US$7 to US$458. The annual cost of den-
osumab differed steeply between countries, from US$608 
to US$1811. Several studies made comparisons between 
denosumab and oral bisphosphonates.
Specifically, eight studies [14, 18, 21, 22, 24–26, 29] 
made comparisons between denosumab and oral alen-
dronate, of which five studies [18, 22, 25, 26, 29] demon-
strated that denosumab was cost effective, and one study 
[21] showed that denosumab was a dominant option if we 
applied US$100,000 per QALY gained as the WTP thresh-
old. In addition, when compared with risedronate and iban-
dronate, denosumab was also shown to be cost effective [25, 
26] or dominant [21, 22]. However, two studies [14, 24] 
showed that denosumab was not cost effective with large 
ICERs when compared with alendronate; this was caused 
by minimal incremental QALYs. In addition, comparisons 
between oral and non-oral bisphosphonates were performed 
in some studies. Three studies [15, 20, 24] were conducted 
between zoledronic acid and oral alendronate, with one 
study indicating that zoledronic acid was dominant [15]; in 
the other two studies, zoledronic acid was not cost effec-
tive or was dominated by alendronate [20, 24]. As a new 
formulation of bisphosphonates, gastro-resistant risedronate 
was cost effective in comparison with alendronate and rise-
dronate in one study [27]. Furthermore, another study com-
pared teriparatide with risedronate, showing that teriparatide 
was not cost effective. Overall, 67% studies (eight of a total 
12 studies) or 82% of comparisons (23 of a total 28 studies) 
suggested that active interventions (denosumab, zoledronic 
acid, gastro-resistant risedronate, or teriparatide) were cost 
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effective when compared with traditional oral bisphospho-
nates. Additionally, comparisons between active interven-
tions were also made in some studies; two studies showed 
that denosumab was cost effective [26] or dominant [21] 
when compared with strontium ranelate. Zoledronate acid 
and teriparatide were dominated by denosumab in another 
two studies [21, 22].
Table 4 presents three studies [16, 20, 28] that estimated 
the cost effectiveness of sequential therapies from the US 
perspective. Hiligsmann et al. [28] analyzed populations 
with different BMD T-scores at baseline, and the study of 
Mori et al. [20] assessed women at different ages and from 
both healthcare and societal perspectives. Hiligsmann et al. 
[28] and Le et al. [16] assessed sequential therapies start-
ing with 1.5 years of abaloparatide or teriparatide, followed 
by 5 years of alendronate as the treatment duration. In the 
study of Mori et al. [20], 2 years of initial treatment with 
teriparatide was followed by 10 years of alendronate. The 
monthly drug costs for abaloparatide were similar between 
studies, at approximately US$1700; the cost of teriparatide 
was from US$1711 to US$3722 per month. Abaloparatide 
followed by alendronate was shown to be dominant when 
compared with teriparatide followed by alendronate in two 
studies [16, 28]. In addition, when compared with a pla-
cebo or no treatment, Hiligsmann et al. [28] showed that 
abaloparatide followed by alendronate was cost saving or 
cost effective in different populations. In the study of Le 
et al. abaloparatide or teriparatide followed by alendronate 
was not cost effective when compared with a placebo fol-
lowed by alendronate [16]. Furthermore, Mori et al. [20] 
compared sequential therapy (teriparatide followed by alen-
dronate) with alendronate alone at different ages and eco-
nomic perspectives, indicating that sequential therapy was 
not cost effective. The high drug costs of abaloparatide and 
Table 3  Cost-effective analyses between oral bisphosphonates and other active drugs for osteoporosis
GP governmental perspective, GR gastro-resistant, HP healthcare perspective, ICER incremental cost-effectiveness ratio, SP societal perspective






Coyle et al. [24] Canada Denosumab vs alendronate 2 US$663/US$123 US$2,376,812
Darbà et al. [25] Spain Denosumab vs alendronate 5 US$608/US$237 US$23,746
Waure et al. [26] Italy Denosumab vs generic alendronate 4 US$842/US$458 US$29,980
Denosumab vs branded alendronate 4 US$842/US$502–528 US$28,462
Karnon et al. [14] Australia Patented denosumab vs generic alendronate 5 US$624/US$230 US$284,397
Mori et al. [18] Japan Denosumab vs alendronate (SP, 65 years) 5 US$799/US$246 US$27,375
Denosumab vs alendronate (SP, 70 years) US$5326
Denosumab vs alendronate (HP, 65 years) US$32,061
Denosumab vs alendronate (HP, 70 years) US$7137
Denosumab vs alendronate (GP, 65 years) US$28,546
Denosumab vs alendronate (GP, 70 years) US$6178
Parthan et al. [21] Sweden Denosumab vs generic alendronate 5 US$733/US$49 Dominant
Silverman et al. [22] USA Denosumab vs generic alendronate 5 US$1811/US$33 US$18,532
Yoshizawa et al. [29] Japan Denosumab vs alendronate 5 US$743/US$289 US$40,969
Darbà et al. [25] Spain Denosumab vs risedronate 5 US$608/US$414 US$7134
Waure et al. [26] Italy Denosumab vs risedronate 4 US$842/US$455 US$17,114
Parthan et al. [21] Sweden Denosumab vs generic risedronate 5 US$733/US$64 Dominant
Silverman et al. [22] USA Denosumab vs risedronate 5 US$1811/US$1874 Dominant
Darbà et al. [25] Spain Denosumab vs ibandronate 5 US$608/US$227 US$3213
Waure et al. [26] Italy Denosumab vs ibandronate 4 US$842/US$819 US$3585
Parthan et al. [21] Sweden Denosumab vs ibandronate 5 US$733/US$544 Dominant
Silverman et al. [22] USA Denosumab vs ibandronate 5 US$1811/US$1462 Dominant
Coyle et al. [24] Canada Zoledronic acid vs alendronate 2 US$298/US$123 US$535,359
Li et al. [15] China Zoledronic acid vs alendronate 3/5 US$536/US$555 Dominant
Moriwaki et al. [30] Japan Zoledronic acid vs alendronate 3 US$350/US$273 Dominant
Hiligsmann et al. [27] France GR risedronate vs alendronate 3 US$58/US$55 US$2401
Azar et al. [13] Iran Teriparatide vs generic risedronate 2 US$1757/US$7 US$522,424
Hiligsmann et al. [27] France GR risedronate vs generic risedronate 3 US$58/US$37 US$2759
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teriparatide largely affected ICERs when compared with no 
treatment, a placebo, and with alendronate alone.
3.3  Critical Appraisal
Table 5 presents the results of the quality assessment of the 
design and conduct of economic evaluations in osteoporo-
sis using the ESCEO-IOF guideline. Substantial differences 
were observed between studies with an average score of 17 
out of 25 (range 2–25). Although some studies followed sev-
eral recommendations of the guideline, room for improve-
ment was observed for most studies.
Figure 2 shows the percentage of studies that fully, 
partially, or did not report the individual recommenda-
tions in the guideline. The most frequently unreported 
recommendations were ‘an additional effect after multiple 
fractures’ (i.e., an additional effect on costs and/or util-
ity should be modeled), ‘adverse events’ (i.e., important 
side effects that have an impact on costs and/or utility 
need to be included), and ‘proportion attributed to the 
fracture’ (i.e., a proportion of excess mortality attributed 
to the fracture should be included). In addition, some rec-
ommendations such as ‘avoid hierarchy of fractures and 
restrictions after fracture events’ (e.g., the absence of a 
non-hip fracture after a previous hip fracture or a limit to 
the number of fracture events) and ‘multiple scenarios’ 
(i.e., include age range and fracture risk levels) were fre-
quently partially reported.
The results of reporting quality assessment are presented 
in Table 6; most recommendations were well reported with 
an average score of 6.8 out of 9 (range 0.5–9). The qual-
ity of reporting was suboptimal for ‘treatment side effects’ 
(i.e., describing the approaches and data sources used for 
costs and utilities effects of adverse events). Furthermore, 
‘medication adherence’ (i.e., describing approaches and 
data sources used for modeling medication adherence) was 
Table 4  Cost-effective analyses of sequential therapy
ABL abaloparatide, ALN alendronate, BMD bone mineral density, HP healthcare perspective, ICER incremental cost-effectiveness ratio, SP soci-
etal perspective, TPTD teriparatide, y years
References Country Population Comparator (treatment duration) Monthly drug costs ICER
Hiligsmann et al. [28] USA BMD T-score ≤ − 3.5, age 70 or 
− 3.5 ≤ BMD T-score ≤ − 2.5 and 
history of one osteoporotic frac-
ture, age 70 y






Le et al. [16] USA Aged ≥ 65 y with a prior vertebral 
fracture











− 3.5 ≤ BMD T-score ≤ − 2.5 and 
history of one osteoporotic frac-
ture, age 70 y
US$40,428
Le et al. [16] USA Aged ≥ 65 y with a prior vertebral 
fracture





Sequential TPTD(1.5y)/ALN(5y) vs 
PBO/ALN(5y)
TPTD US$3722 US$991,854





Age 70 y (SP) Sequential TPTD(2y)/ALN(10y) vs 
ALN(10y)
US$335,973
Age 75 y (SP) Sequential TPTD(2y)/ALN(10y) vs 
ALN(10y)
US$285,170
Age 80 y (SP) Sequential TPTD(2y)/ALN(10y) vs 
ALN(10y)
US$296,063
Age 65 y (HP) Sequential TPTD(2y)/ALN(10y) vs 
ALN(10y)
US$449,695
Age 70 y (HP) Sequential TPTD(2y)/ALN(10y) vs 
ALN(10y)
US$342,794
Age 75 y (HP) Sequential TPTD(2y)/ALN(10y) vs 
ALN(10y)
US$293,416
Age 80 y (HP) Sequential TPTD(2y)/ALN(10y) vs 
ALN(10y)
US$304,514
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poorly reported in some articles [10–13, 15, 17, 23, 26, 33], 
as well as ‘treatment effect after discontinuation’ in six arti-
cles (i.e., these studies did not assume a linear decrease of 
the effect after discontinuation for a period similar to the 
duration of treatment) [10–13, 23, 24].
3.4  Key Drivers of Cost Effectiveness
Several drivers of cost effectiveness were identified, includ-
ing baseline fracture risk, drug effect on the risk of fractures, 
drug cost, and medication adherence/persistence.
3.4.1  Baseline Fracture Risk
Most studies indicated that the increase of baseline fracture 
risk and the age of patients were associated with favora-
ble results of cost-effectiveness analyses of osteoporotic 
drugs. For instance, Moriwaki et al. [30] indicated that the 
incremental costs and incremental QALYs of zoledronic 
acid compared with alendronate tended to be small, with 
an increase of T-scores. Moreover, Chokchalermwong et al. 
[23] reported that, compared to no treatment, the ICER 
of bisphosphonates was 130,049 THB per QALY when 
starting the drug from the age of 65 years, with a BMD 
T-score ≤ − 2.5. However, denosumab was cost effective 
from the age of 80 years and over.
3.4.2  Drug Effect on the Risk of Fractures
Twelve studies [15, 18, 20–23, 25, 29–32, 36] reported that 
the cost effectiveness result of osteoporotic drugs is most 
sensitive to changes in the effect of osteoporotic drugs on the 
risk of fractures. Silverman et al. [22] indicated that when 
the relative risk of hip fracture with denosumab is lowered 
from 0.38 (baseline) to 0.18, denosumab still dominates 
the generic alendronate. However, when this relative risk is 
increased to 0.78, denosumab is no longer a cost-effective 
option. This finding is similar to the study of Parthan et al. 
[21] and Yoshizawa et al. [29]. In addition, Moriwaki et al. 
[30] reported that the relative risk of hip fracture with zole-
dronic acid had a relatively strong effect on the estimated 
incremental net monetary benefit; compared to alendronate, 
zoledronic acid could be a cost-effective option if the rela-
tive risk was equal to 0.34 (lower limit).
3.4.3  Drug Cost
Variation in drug costs could lead to different cost-effec-
tiveness results of anti-osteoporosis drugs. The strong 
effect of drug cost was reported in several studies [13, 14, 
20, 23, 27–30, 33, 34]. Mori et al. [20] compared sequen-
tial therapy (teriparatide followed by alendronate) to alen-
dronate alone and reported that results were most sensitive 
to the changes in the estimated cost of teriparatide. If the 
cost of a generic/biosimilar was estimated to be 15% of 
the brand (i.e., 85% less), the annual cost of teriparatide 
would be $6490 for a 65-year-old cohort; or if the cost of 
a generic/biosimilar was estimated to be 35% of the brand 
(i.e., 65% less), the annual cost of teriparatide would be 
$11,461 for a 75-year-old cohort; the ICERs of sequential 
teriparatide/alendronate were below the WTP threshold 
of $150,000/QALY. Moriwaki et al. [30] also reported 
that if the cost of zoledronic acid was lowered by 30%, 
zoledronic acid could be a cost-effective option compared 
with alendronate. Additionally, Karnon et al. [14] indi-
cated that there is a near-zero probability that denosumab 
is cost effective at a threshold of $100,000/QALY com-
pared with alendronate at the current price; however, if the 
price of denosumab was reduced by 50%, the incremental 
cost per QALY gained falls to $50,068.
3.4.4  Medication Adherence/Persistence
Anti-osteoporosis medications have shown to be effective in 
reducing fracture risk; however, as a chronic disease, non-
adherence to pharmacological treatment in osteoporosis is 
a well-recognized problem, which would result not only in 
deteriorating clinical outcomes, but also in decreased cost 
effectiveness of pharmacotherapy. Several studies [18, 20, 
27, 29, 31, 34] reported that the persistence and adherence 
rates of osteoporosis medications have marked effects on 
the cost-effectiveness ratios. For instance, Mori et al. [18] 
indicated that denosumab was cost effective or even cost 
saving in comparison with weekly oral alendronate, mainly 
driven by the higher persistence rate of denosumab leading 
to higher efficacy. In addition, Hiligsmann et al. [27] also 
reported that the ICERs of gastro-resistant risedronate were 
markedly affected by the incremental difference in persis-
tence between gastro-resistant risedronate and the active 
comparator treatment. Moreover, the study of Chen et al. 
[31] demonstrated that medication persistence and adher-
ence had a great impact on clinical and cost effectiveness, 
high raloxifene persistence and adherence improved clini-
cal effectiveness, but the costs were also higher. Raloxifene 
treatment became cost effective compared with a conven-
tional treatment strategy if raloxifene persistence and adher-
ence decreased by 30–50%.
4  Discussion
This updated review identified 27 economic evaluations 
of drugs for osteoporosis published between July 2013 
and 2019. Twelve active drugs were assessed in the stud-
ies, including bisphosphonates (alendronate, etidronate, 
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risedronate, gastro-resistant risedronate, ibandronate, and 
zoledronic acid), romosozumab, raloxifene, strontium 
ranelate, denosumab, teriparatide, and abaloparatide. 
When compared with traditional oral bisphosphonates, 
67% of the studies (eight of the total 12 studies) or 82% of 
the comparisons (23 of the total 28 comparisons) showed 
that the alternative drugs (denosumab, zoledronic acid, 
gastro-resistant risedronate, and teriparatide) were cost 
effective or dominant at the WTP threshold of US$100,000 
per QALY gained. In particular, most studies suggested 
that denosumab was a cost-effective or dominant option 
compared with oral bisphosphonates. It should however 
be noted that recent studies have shown a rapid decrease 
of BMD and an increased risk of vertebral fractures after 
discontinuation of denosumab [37, 38] and that these 
effects have not been included in economic evaluations; 
accordingly, the cost effectiveness of denosumab could 
be over-estimated.
Additionally, within the total 27 studies, the source of 
funding and the role of the funder were fully reported in only 
14 studies. It is further interesting to note that three [22, 25, 
26] out of eight studies conducted comparing denosumab 
with oral bisphosphonates, showing that denosumab was 
cost effective or dominant, were funded by industry. For the 
remaining five studies that did not mention funding or had 
no funding, only three (60%) indicated that denosumab was 
cost effective or dominant. The potential bias in industry-
sponsored studies may therefore exist; however, given the 
limited studies, it is difficult to draw a clear conclusion. 
Previously, another study [39] comparing economic evalu-
ations of bisphosphonates for the treatment of osteoporosis 
suggested that the funding source (industry vs non-industry) 
did not seem to significantly affect the reporting of ICERs 
below the US$20,000 and US$50,000 thresholds.
Furthermore, some new formulations of bisphosphonates 
also led to a higher health benefit than traditional oral tablet 
bisphosphonates. One of the included studies showed that 
gastro-resistant risedronate was cost effective when com-
pared with traditional oral alendronate [27]. In addition, 
some recent studies also indicated that new effervescent 
formulation of alendronate could be an intriguing option in 
reducing the occurrence of adverse gastrointestinal events 
in anti-osteoporosis treatment, thus increasing adherence 
to therapy and anti-fracture efficacy [40]. More research is 
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Fig. 2  Proportion of studies meeting individual items recommended in ESCEO-IOF guideline (total studies: 27). BMD bone mineral density, 
QALY quality-adjusted life-year, RCTs randomized controlled trials
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needed to investigate both the clinical and economic benefits 
of these new formulations of oral bisphosphonates.
With emerging evidence about the value of sequential 
therapy [41, 42], sequential therapy was included in three 
studies [16, 20, 28]. When mutually comparing anabolic 
agents, sequential treatment starting with abaloparatide fol-
lowed by alendronate was shown to be dominant compared 
with sequential therapy starting with teriparatide followed 
by alendronate. These three studies also compared the cost 
effectiveness of sequential therapy with no treatment, pla-
cebo, or alendronate alone, indicating mixed results. Incre-
mental cost-effectiveness ratios were strongly affected by 
the extremely high drug costs of anabolic agents. One study 
[20] demonstrated that their results were sensitive to the 
cost of teriparatide, reporting that the cost of a generic/bio-
similar product needed to be 65–85% lower than the brand 
for sequential teriparatide/alendronate to be cost effective.
After our search period, another study suggested that 
sequential treatment starting with abaloparatide followed 
by alendronate was cost effective in comparison to generic 
alendronate monotherapy for US postmenopausal women 
aged ≥ 60 years at an increased risk of fractures. This also 
dominated sequential treatment starting with alendronate 
followed by abaloparatide and then again by alendronate 
[43].
This review updates a previous systematic review of cost-
effectiveness analyses of drugs for postmenopausal osteopo-
rosis [6]. The previous review identified 39 economic evalu-
ations of drugs in postmenopausal osteoporosis published in 
the period 2008–13, an average of 6.5 studies per year. In 
our review, 4.5 studies per year were identified. Given that 
new osteoporosis medications continue to emerge on the 
market, the previous review does not include some medi-
cations that were not available that time, but are currently 
frequently used. The cost effectiveness of some medications 
was not conclusive because of the limited number of studies 
in the previous review, but the evidence became clearer in 
our updated review. In addition, with newer evidence being 
available after the publication of the previous review, the 
comparator in the economic evaluation might also changed. 
For example, vitamin D and calcium (or no treatment) were 
common comparators in previous studies. However, most 
studies (74%) in our review made comparisons between 
active osteoporotic interventions and traditional oral bispho-
sphonates, as well as mutual comparisons between different 
alternatives.
Moreover, in comparison with the previous review, 
where evaluations were mainly conducted in Europe, many 
evaluations in the updated review were conducted outside 
of Europe and especially in Asia, where osteoporosis is an 
increasing burden [44]. Thirty-three percent of the studies 
in our review applied the Markov microsimulation model in 
comparison with 21% in the previous review, indicating the 
increasing use of Markov microsimulation model in recent 
years, which supports the suggestion that the Markov micro-
simulation model is an evolution of a health economic model 
used in osteoporosis. The Markov individual state-transition 
model overcomes the memory-less nature of the Markov 
cohort model and is preferred to capture all the interactions 
between events and the changing risks of future fractures 
and mortality [45].
There are several extra findings identified in our review 
in comparison with the previous review. However, a com-
parison between the two studies remains difficult owing to 
the large heterogeneity in country setting, model structure, 
fracture risk, drug costs, and incorporation of medication 
adherence. In addition, the use of  FRAX® or  GARVAN® 
tools [46] indicates a slight increase (5%) in comparison 
with studies included in the previous review, but it is still 
inadequate (22%).
To assess the quality of included studies, unlike the 
general checklist applied in the previous review, we used 
an osteoporosis-specific guideline [7] to critically appraise 
the studies included in this review. In comparison with 
the general quality assessment tools relied on in the previ-
ous review, the osteoporosis-specific guideline serves as 
a minimum standard for all economic analyses in osteo-
porosis; the guideline’s specificity enables better identi-
fication of unmet quality issues within recent studies and 
indicates some highly important criteria that should be met 
and improved in future studies, and further helps to reduce 
inter-study heterogeneity, thereby facilitating inter-study 
comparisons. Although a few studies followed several of 
the guideline’s recommendations, given that most of the 
studies were published prior to the osteoporosis-specific 
guideline, the guide was not available to assist researchers 
in designing appropriate and high-quality economic eval-
uations, which may be why most studies did not adhere 
to several recommendations/criteria of the guideline and 
scored poorly for some criteria. Room for improvement 
was observed.
With regard to osteoporosis-specific recommendations, 
the frequently unmet/unreported recommendations such as 
‘an additional effect after multiple fractures on cost and/
or utility’, ‘important adverse events’, and ‘a proportion of 
excess mortality attributed to the fracture’ should be mod-
eled/included in future studies. As for osteoporosis-specific 
checklist for reporting, considering several partially or not 
reported recommendations including ‘treatment side effects’, 
‘medication adherence’, and ‘treatment effect after discon-
tinuation’ would limit transparency, comparability, and use 
by decision maker; these missing or partially reported rec-
ommendations should receive more attention and be mod-
eled/included in future studies. Therefore, the osteoporosis-
specific guideline, which supplements the generally accepted 
methodologic standards, can be useful in improving the 
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transparency, quality, and comparability of economic evalu-
ations in osteoporosis, thus increasing its potential for use by 
decision makers and leading to a more effective allocation 
of resources [7].
Moreover, it is important that researchers should be aware 
of and use the guideline. Interestingly, since the publica-
tion of the ESCEO-IOF guideline (between October 2018 
and August 2020), nine economic evaluations have used 
and referenced the guideline. Specifically, these nine stud-
ies all reported that the conduct of the economic evalua-
tion adheres to this recent published osteoporosis-specific 
guideline. However, only four studies [20, 28, 34, 47] clearly 
showed how their studies followed the recommendations of 
the guideline. Therefore, to successfully implement this 
guideline, we recommend that future studies include a table 
in the main text or appendix stating clearly how the criteria 
were met, and/or the reasons for non-adherence (if appro-
priate), which would lead to improved study transparency.
Additionally, some key drivers of cost effectiveness were 
identified in this review, including baseline fracture risk, 
drug effect on the risk of fractures, drug cost, and medi-
cation adherence/persistence. These key drivers were fre-
quently reported to be the most influential factors in the cost-
effectiveness ratio, and should therefore be incorporated in 
future economic evaluations.
Although the present study followed recommendations 
for conducting reviews of economic evaluations [48], there 
may have been some potential limitations to our study. First, 
because of limited space in Table 2 and for clarity, only 
base-case results were included in our results analysis. Sec-
ond, reviewers involved in the quality assessment proposed 
different opinions in scoring for some recommendations; 
discrepancies in rating were resolved by a third reviewer 
(MH) and reached a consensus with the first author (NL). In 
addition, differentiating between partially or fully reported 
was difficult for some recommendations; the final interpreta-
tion/assessment was performed by the first author in agree-
ment with a third reviewer (MH), who assessed all papers. 
Third, although the osteoporosis-specific guideline aimed 
to complement and align with most general guidelines for 
economic evaluations, some differences can be observed. 
For instance, the ESCEO-IOF guideline treats one-way and 
probabilistic sensitivity analyses equally in scoring, while 
other guidelines may treat them separately. Fourth, some 
key drivers of cost effectiveness were identified during 
the review of the articles. We did not perform a system-
atic quantitative assessment to identify key drivers of cost 
effectiveness.
5  Conclusions
In comparison with evaluations listed in a previous review, 
recent economic evaluations were conducted in more coun-
tries, and included more active drugs and sequential therapy 
as comparators. A comparison between studies remains dif-
ficult. In total, this updated review included 27 studies on 
the cost effectiveness of drugs for osteoporosis, suggest-
ing that some active interventions (denosumab, zoledronic 
acid, gastro-resistant risedronate, or teriparatide) were cost 
effective or dominant when compared with oral bisphos-
phates. However, given the limited number of studies on 
the cost-effectiveness of sequential therapy that have been 
conducted so far, further research would be needed to inves-
tigate adequate evidence of the beneficial effect of this new 
form of intervention over single anti-osteoporosis interven-
tions alone. In addition, the results of a quality appraisal 
indicate that greater adherence to the osteoporosis-specific 
guideline is expected to improve the transparency, quality, 
and comparability of future studies.
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